All enrolled sufferers who acquired no less than a person dose of zosuquidar or placebo throughout induction had been monitored for the occurrence of adverse activities (439 sufferers, 219 on zosuquidar and 210 on placebo). The most common adverse events were related to the duration of prolonged and sizeable myelosuppression https://gefapixant22098.losblogos.com/27664385/il-17-modulator-4-an-overview